Research could help create better and safer immunotherapy treatments for mesothelioma. Immunotherapy is a fast growing and exciting way to treat cancer because it uses the body’s own immune system to treat cancer instead of harmful drugs like chemotherapy. Immunotherapy can be way more effective than typical treatments, but it[…]
Full Archive
UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)
This is a single arm, prospective, interventional, multicenter phase 2 study of the combination of niraparib and dostarlimab in patients with advanced non-small cell lung cancer (NSCLC) and/or malignant pleural mesothelioma (MPM), and positive for PD-L1 expression (TPS ≥ 1%) and germline or somatic mutations in the DNA homologous recombination repair (HRR) genes.
GPS Vaccine is Effective in Mesothelioma Patients When Paired with Opdivo
A new cancer vaccine was found to be effective in mesothelioma patients alongside Opdivo in a new study. It was studied in people whose cancer no longer responded to standard chemotherapy. The phase I clinical trial took place at the Memorial Sloan Kettering Cancer Center and it involved the galinpepimut-S[…]
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving stereotactic body radiation therapy and immunotherapy may improve the tumors response to the treatment and decrease side-effects.
Vinorelbine Could Soon be Used to Treat Mesothelioma
Vinorelbine could be a useful second-line treatment for patients with relapsed mesothelioma. A phase II clinical trial examined vinorelbine to see how effective it is in patients who had their pleural mesothelioma progress after platinum chemotherapy treatment. Doctors believe vinorelbine could be another option for patients instead of the standard[…]
Pleural Effusion in Mesothelioma Patients May Affect Survival
Pleural effusion may affect mesothelioma survival. Pleural effusion is a buildup of fluid around the lungs that can be caused by multiple illnesses including heart failure, kidney and liver disease, pleural mesothelioma, and other cancers. The only way to treat this condition is to drain the fluid, which makes it[…]
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
Primary Outcome Measures Objective response rate (ORR) [ Time Frame: Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximatively 9 months after the last participant receive first dose. ] Objective response rate (ORR), defined as the proportion of participants who have a confirmed complete response (CR) or[…]
Adjuvant Radiotherapy Does Not Improve Survival in Pleural Mesothelioma Patients
Adjuvant radiotherapy might not be the best treatment for mesothelioma sufferers because researchers at Duke and Stanford found that this therapy does not help patients live longer. The researchers analyzed a database of pleural mesothelioma patients at Duke and a national registry of patients. The research looked at the outcomes[…]
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Primary Outcome Measures Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 28 Days ] A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by[…]
Mesothelioma Patients with High Levels of the PD-L1 Protein Have Shorter Survival
Unfortunately for mesothelioma patients with high levels of the PD-L1 protein, they have a worse overall survival compared to patients who have lower levels. A European study looking at 200 patients wanted to see if PD-L1 and PD-1, popular targets for immunotherapy drugs, impact survival independently without immunotherapy drugs present.[…]
